Brigatinib AP26113 (Brigatinib) AP26113 (Brigatinib)
1,we produce and sell good chemicals around the world.
2,our success rate is about 95%. this means, if customer order is accepted, the probability that the customer will obtain the ordered substances, is 95%.
3,our staff consists of highly qualified individuals with bsc, msc and ph.d degrees in chemistry, as well as excellent carbohydrates,nucleosides, small molecules and rare chemicals.
4,imaginechem's chemists are skilled at performing complex, multi-step syntheses and solving difficult chemistry-related problems. because of our better, concentracted size and low overheads, we are able to offer prompt quotations, very competitive prices, high quality products and fast delivery.
5,all chemicals are typically >97% for building blocks, the structure and purity is confirmed by nmr and lc-ms. intermediates and final products are analyzed by gc, hplc, ir, nmr, ms, elemental analysis, atom-absorpting analysis and crystallographical methods.
165,Customers-oriented strategy, exclusive supply chain management, professional R&D team, experienced production workers, energetic sales team enable us to offer best service andgood-value products to all of our customers and gradually reach our final goals: becoming global leading supplier for portable products and solutions.
Product Name: Brigatinib
Synonyms: Brigatinib;AP26113 (Brigatinib);Brigatinib, AP26113;5-Chloro-N4-[2-(dimethylphosphinyl)phenyl]-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-2,4-pyrimidinediamine;5-chloro-N4-(2-(dimethylphosphoryl)phenyl)-N2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrimidine-2,4-diamine;brigatib;140455;Bogtinib (AP26113)
CAS: 1197953-54-0
form solid
color White to off-white
General Description Brigatinib (AP26113,1197953-54-0) is a medicine used to treat cancer that suppresses epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK). Brigatinib is a selective agonist against variations of EGFR as opposed to the wild mutant forms. The drug also illustrates selectivity against the ALK-EML4 fusion gene, which is a fundamental aspect of the modification of susceptible lung parenchyma. Brigatinib is prescribed for patients with specific abnormal genes and when the non-small cell lung cancer (NSCLC) is non-responsive to management with other medications. Brigatinib is classified as a kinase inhibitor, whose mechanism of action entails suppressing the action of abnormal proteins that enhance the multiplication of cancer cells.
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View